Table 2. Parameters of Oxidative Stress in Type 2 Diabetic Patients and the Effect of 3 Months Adjunct Treatment with Captoprila.
| control | before treatment | 1 month treatment | 3 months treatment | |
|---|---|---|---|---|
| TBARS (nmol/mL) | 2.52 ± 0.46 | 4.87 ± 1.21a | 4.69 ± 1.30a | 3.99 ± 1.02a |
| (93.3%) | (+86.1%) | (+58.3%) | ||
| tGSH (nmol/mL) | 2.99 ± 0.48 | 1.57 ± 0.21 a | 1.82 ± 0.38 a | 2.33 ± 0.28 a,b,c |
| (−47.5%) | (−39.1%) | (−22.1%) | ||
| GSH (nmol/mL) | 2.76 ± 0.49 | 0.73 ± 0.13 a | 0.88 ± 0.30 a,b | 1.61 ± 0.28 a,b,c |
| (−73.6%) | (−68.1%) | (−41.7%) | ||
| GSSG (nmol/mL) | 0.12 ± 0.01 | 0.42 ± 0.05 a | 0.40 ± 0.05 a | 0.36 ± 0.04 a,b |
| (+250.0%) | (+233.3%) | (+200.0%) | ||
| GSH/GSSG ratio | 23.9 ± 5.4 | 1.7 ± 0.3 a | 2.6 ± 0.4 a | 4.5 ± 1.1 a,b |
| redox potential (mV) | –139 ± 4.7 | –66 ± 4.0 a | –75 ± 4.2 a,b | –88 ± 4.9 a,b,c |
| (−52.5%) | (−46.0%) | (−36.7%) | ||
| ox-LDL-Ab (mU/mL) | 304.1 ± 61.5 | 457.9 ± 94.5 a | 400.3 ± 76.9 a | 336.9 ± 69.8 b |
| (+50.2%) | (+31.6%) | (+10.8%) |
a
Data are presented as mean (SD). Superscript letters indicate significant differences: asignificantly different from control group, bsignificantly different from patient group before treatment, and csignificantly different from patient group after 1 month of treatment, where p < 0.05. Number in parentheses represents percentage deviation from control value.